The authors suggest that FMD-induced depletion of TNBC CSCs when tumors are in a less advanced stage could enormously enhance the efficacy of subsequent treatments targeting both CSCs (such as the FMD) and more differentiated cancer cells (such as PI3K/AKT/mTORC1 inhibitors) in late-stage cancers (Salvadori et al., 2021). The gene discussed is AKT1; the disease is cancer.